Cargando…

Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents

Activation of indirect pathway medium spiny neurons (MSNs) via promotion of cAMP production is the principal mechanism of action of current antipsychotics with dopamine D(2) receptor antagonism. TAK‐063 [1‐[2‐fluoro‐4‐(1H‐pyrazol‐1‐yl)phenyl]‐5‐methoxy‐3‐(1‐phenyl‐1H‐pyrazol‐5‐yl)pyridazin‐4(1H)‐one...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Kazunori, Harada, Akina, Suzuki, Hirobumi, Capuani, Clizia, Ugolini, Annarosa, Corsi, Mauro, Kimura, Haruhide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817828/ https://www.ncbi.nlm.nih.gov/pubmed/29417763 http://dx.doi.org/10.1002/prp2.372

Ejemplares similares

S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
por: Suzuki, Kazunori, et al.
Publicado: (2018)

Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
por: Harada, Akina, et al.
Publicado: (2015)

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
por: Macek, Thomas A, et al.
Publicado: (2020)

The mammalian target of rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior
por: Ramírez-Jarquín, Uri Nimrod, et al.
Publicado: (2020)

Cataleptic Hysteria
Publicado: (1856)

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
por: Tsai, Max, et al.
Publicado: (2016)

Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium
por: Jain, Rajan, et al.
Publicado: (2017)

Olanzapine Versus Haloperidol: Which Can Control Stuttering Better?
por: Shaygannejad, Vahid, et al.
Publicado: (2013)

Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia
por: Tanaka, Maiko, et al.
Publicado: (2019)

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events
por: Goldsmith, Paul, et al.
Publicado: (2017)

Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
por: Mondelli, V, et al.
Publicado: (2013)

Letter to editor regarding “comparison of efficacy of haloperidol and olanzapine in the treatment of delirium”
por: Kumar, Pawan, et al.
Publicado: (2019)

Effect of Haloperidol and Olanzapine on Hippocampal Cells’ Proliferation in Animal Model of Schizophrenia
por: Osacka, Jana, et al.
Publicado: (2022)

Co-Administration of Subeffective Anxiolytic Doses of Diazepam and Hydroxyzine in Elevated Zero-Maze in Mice
por: Naghibi, Bijan, et al.
Publicado: (2011)

Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents
por: Harada, Akina, et al.
Publicado: (2019)

Differential Effects of Olanzapine and Haloperidol on MK-801-induced Memory Impairment in Mice
por: Song, Jae Chun, et al.
Publicado: (2016)

TAK-071, a muscarinic M(1) receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys
por: Kurimoto, Emi, et al.
Publicado: (2019)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang, Fuyin, et al.
Publicado: (2018)

The antipsychotic drugs olanzapine and haloperidol modify network connectivity and spontaneous activity of neural networks in vitro
por: Dzyubenko, Egor, et al.
Publicado: (2017)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

The Cataleptic, Asymmetric, Analgesic, and Brain Biochemical Effects of Parkinson's Disease Can Be Affected by Toxoplasma gondii Infection
por: Taherianfard, Mahnaz, et al.
Publicado: (2020)

Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin
por: Chaudhry, Haroon Rashid, et al.
Publicado: (2008)

Haloperidol, but not olanzapine, may affect expression of PER1 and CRY1 genes in human glioblastoma cell line
por: Mokros, Łukasz, et al.
Publicado: (2016)

Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal
por: Dulal, Soniya, et al.
Publicado: (2019)

Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial
por: van der Vorst, Maurice J.D.L., et al.
Publicado: (2019)

An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home
por: Lyu, Xiao-Juan, et al.
Publicado: (2022)

Author Correction: Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
por: Yurgelun-Todd, Deborah A., et al.
Publicado: (2019)

A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia
por: Singh, Om Prakash, et al.
Publicado: (2008)

Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)
por: García-Cabeza, Ignacio, et al.
Publicado: (2001)

Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial
por: Xue, Xiaobin, et al.
Publicado: (2018)

A review of a recently published guidelines' “strong recommendation” for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine
por: Noel, Christopher
Publicado: (2019)

Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial
por: Chan, Esther W., et al.
Publicado: (2021)

5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats
por: Mahmoudi, J., et al.
Publicado: (2011)

P063 Optogenetics for Obstructive Sleep Apnea
por: Knapman, F, et al.
Publicado: (2021)

Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss
por: Crum, W. R., et al.
Publicado: (2016)

Second-Generation Parenteral Antipsychotic (Olanzapine) as a First-Line Treatment for Acute Undifferentiated Agitation in the Emergency Department in Comparison With Haloperidol
por: Singh, Adheera P, et al.
Publicado: (2023)

Determination of Chlorpromazine, Haloperidol, Levomepromazine, Olanzapine, Risperidone, and Sulpiride in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
por: Khelfi, Abderrezak, et al.
Publicado: (2018)

Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia
por: Sathish Kumar, S. V., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_28uqfvcvq4ig7q694kl2lr191e